Novel MIA™-T Percutaneous Tricuspid Annuloplasty Systemdiscovered for the treatment of moderate-severe tricuspid regurgitation (TR).The system is used for the treatment oftricuspid regurgitation (TR) via a 12F catheter-based system.
There has been an increase in the treatment of tricuspid regurgitation due to early clinical data for catheter-based technologies have shown significant promise in improving the patient’s quality of life with severe tricuspid regurgitation (TR).
MIA-T system designed with relative simplicity, safety and securitywill help for the treatment of patients suffering with moderate-severe tricuspid regurgitation. In addition, the system consists of various advantages for treating a broad range of patients and in overall ease of use.
In U.S, it is expected that nearly 1.6 million people suffer from TR and only 8,000 receive surgical treatment today.
The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for MIA™-T Percutaneous Tricuspid Annuloplasty System for the treatment of tricuspid regurgitation (TR).